Adherence to medication can be thought of as a decision making process that includes the consideration of the pros and cons of change. It involves evaluation on self-efficacy to change and attitudes held about the efficacy of medication treatment. HIV infected people who are sick, who are experiencing HIV symptoms or the negative side effects of their medications. A quality patient-provider relationship can also be identified as an important source of adhering to HIV medications. Understanding the predicament of the majority of HIV positive persons, conceived a breakthrough in HIV treatment administration. Surely, there are ways anyone can do to better adhere to ones treatment regimens but Vonavir/Atripla took all the burden away.
Atripala is the first multi-class
antiretroviral drug available in the United States and marked the first collaboration of two US pharmaceutical companies to combine their patented anti-HIV drugs into one product. It was approved by the Food and Drugs Administration on July 12, 2006. Atripla is the result of unprecedented effort between Gilead Sciences the manufacturer of Emtriva and Viread, with Bristol-Myers Squibb the maker of Sustiva.This wonderful innovation of a pill combines the active ingredients of Sustiva (efavirenz) a Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) with Emtriva (emtricitabine) and Veriad (tenofovir disoproxil fumarate), two Nucleoside Reverse transcriptase Inhibitor (NRTI). Dosing of Atripla is suitable to be taken at bedtime to improve tolerability of the nervous system and it is not recommended for HIV patients under 18 years old.
Mild to moderate rash is a common side effect of efavirenz. In controlled clinical trials, 26% of patients treated with efavirenz experienced new-onset skin rash compared with 17% of patients treated in control groups. Skin discoloration, associated with emtricitabine, may also occur. ATRIPLA should be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement, or fever. Atripla can significantly simplify a drug treatment regimen by reducing the pill burden, helping to increase adherence and thus reducing potential development of viral resistance to the drugs. This may result in longer term effectiveness of the drug regimen. Learn more, symptoms of HIV
Because there is no vaccine for HIV, the only way people can prevent infection with the virus is to avoid behaviors putting them at risk of infection, such as sharing needles and having unprotected sex.
Many people infected with HIV/AIDS have no symptoms. It is therefore difficult to know with certainity whether a sexual partner is infected with HIV unless they have taken a HIV test and not engaged in risky behavior since.
Abastaining from sex or using a condom will offer protection during oral,anal and vaginal sex. Only water based lubes should be used when using male condoms.
There is some evidence that shows spermicides can kill HIV, researchers have not proved that these products can actually prevent transmission.
Recently, NIAID-supported two studies that found adult male medical circumcision reduces a man’s risk of acquiring HIV infection by approximately 50 percent. The studies, conducted in Uganda and Kenya, pertain only to heterosexual transmission. As with other prevention strategies, male circumcision is not completely effective at preventing the transmission of HIV. Circumcision will be most effective when it is part of a more complete prevention strategy, including the ABCs (Abstinence, Be Faithful, Use Condoms) of HIV prevention.
Vaccines help the immune system to recognize a pathogen so that it can fight it off if it shows up. In face of extraordinary advances in understanding both HIV and the immune system a successful HIV vaccine continues to be unattainable. This why we primarily reley on HIV medications like Kaletra (Aluvia), and Combivir.
HIV attacks CD4+ T cells, the most important part of the immune system that coordinates and directs the activities of other types of immune cells that combat intruding microbes. For a vaccine to be effective, it will need to be able to activate these cells-a difficult feat if they’re being infected and destroyed by the virus.Scientists have not identified the correlates of immunity, or protection, for HIV and are still trying to design vaccines to induce the appropriate immune responses necessary for protection.
Unlike other viral diseases for which investigators have made successful vaccines, there are no documented cases of complete recovery from HIV infection. So, HIV vaccine research has no actual human model of recovery from an infection and subsequent protection from re-infection to help it. HIV will continually mutate in an infected person while it recombinds to evolve into brand new strains. This extensive diversity of HIV poses a challenge to vaccine design as an HIV vaccine would need to protect against many different strains of the virus circulating throughout the world. Conventional vaccines have had to protect against one or a limited number of strains.
AIDS HIVwas first reported in the United States in 1981 and has since become a major worldwide epidemic. AIDS is caused by the human immunodeficiency virus, or HIV. By destroying or harming cells of the body’s immune system, HIV eventually destroys the body’s ability to fight off infection. People who have been diagnosed with HIV/AIDS can get dangerous infections called opportunistic infections. These infections are caused by microbes such as viruses or bacteria that usually do not make healthy people sick.
HIV Causes AIDS
Since 1981, more than 980,000 cases of AIDS have been reported in the United States to the Centers for Disease Control and Prevention (CDC). The CDC states that more then 1,000,000 Americans have been infected with HIV, 25% of which are unaware of their infection. The HIV epidemic is increasing the most amoung minority populations and is leading killer of black males between age 25 and 44. According to CDC, AIDS affects nearly seven times more African Americans and three times more Hispanics than whites. In recent years, an increasing number of African-American women and children are being affected by AIDS HIV.
HIV kills CD4 + cells, which are white blood cells that help maintain the immune system. As the virus kills those cells, the patient infected with HIV is less able to fight off new infections and diseases, this ultmately results in AIDS.
Generally people who are infected with HIV can have the viruses for a realtively long period before the immune system starts to fail. There is a strong connection between HIV in the blood and the decline of CD4 cells and the onset of AIDS. Antiretroviral medications can help slow the infection, save CD4+ T cells and ramatically slow the advance of HIV infection.